Sanofi selects Burgopak slider for Maalox Plus

Published: 13-Oct-2011
Packaging Pharmaceutical

Yellow carton and orange blister stand out on shelf

Sanofi is using the Burgopak slider for packaging its heartburn treatment, Maalox Plus, which was launched in Italy in September.

Maalox Plus is one of four products to be launched by Sanofi in the Burgopak format. The first was Dolipranelib for the French OTC market in September 2010. Sanofi has also launched Menthe and Citron versions of the drug in this packaging.

The Burgopak’s compact size and engaging opening system is complimented by a bright yellow outer carton and contrasting orange blister chosen by Sanofi. This combination allows the Maalox Plus product to stands out from competitors on pharmacy shelves and help increase consumer brand recognition. The Burgopak slider design itself focuses on patient compliance and ensures that all vital information is clearly displayed and available whenever the product is used.

The Burgopak slider was launched into the pharmaceutical market in 2008.

  • Companies:
  • Burgopak
  • Sanofi
See more

You may also like

Packaging

Haleon and Sanofi to explore sustainable packaging alternatives

Read more
The Bottle Collective’s mission is to industrialise a recyclable high-speed, low-cost dry moulded fibre bottle process

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. Gerresheimer acquires Bormioli Pharma Group through Blitz LuxCo Sarl merger Gerresheimer and Bormioli Pharma will merge to provide the biotech and pharmaceutical industries with primary packaging solutions, dosing systems, closure solutions and accessories
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. AstraZeneca appoints Iskra Reic as its International Executive Vice President Iskra will be responsible for championing AstraZeneca's growth across key markets globally, as well as business strategy development
  5. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Packaging

Haleon and Sanofi to explore sustainable packaging alternatives

The Bottle Collective’s mission is to industrialise a recyclable high-speed, low-cost dry moulded fibre bottle process
Ingredients

Therapeutics: nirsevimab for RSV prophylaxis

Respiratory syncytial virus (RSV) is a common and contagious virus that infects the respiratory tract
Finance

Sanofi to acquire Principia Biopharma

The late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases has entered into a definitive agreement with Sanofi
Ingredients

Therapeutics: isatuximab for multiple myeloma

Despite the advances in treatment that have been made in recent years, multiple myeloma blood cancer remains incurable
Manufacturing

Sanofi opens its first digitally enabled continuous manufacturing facility

The biologics manufacturing facility in Framingham, Massachusetts, uses paperless and data-driven manufacturing technologies
Drug Delivery

Sanofi and Abbott partner to integrate glucose sensing and insulin delivery

Collaboration aims to develop tools that combine Abbott’s FreeStyle Libre technology with insulin dosing information for future smart pens, insulin titration apps and cloud software
Manufacturing

Sanofi and Pfizer engage Biovac Institute with vaccines production in South Africa

Facility in Cape Town will start production of Sanofi’s Hexaxim in 2020, and Pfizer’s anti-pneumonia Prevnar 13 in 2021
Subscribe now